Effect of isofebrifugine on the proliferation and invasion of human gastric cancer cells via MMP

Jin Xu; Jianbo Wu; Chuankang Tang

doi:10.14715/cmb/2019.66.1.4

Issue

Vol. 66 No. 1: Issue 1

Issue Published : April 25, 2020

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Effect of isofebrifugine on the proliferation and invasion of human gastric cancer cells via MMP

https://doi.org/10.14715/cmb/2019.66.1.4

Jin Xu

Department of Gastroenterology, The Affliliated Hospital of Southwest Medical University, Luzhou, PR China

Jianbo Wu

Drug Discovery Research Center, Southwest Medical University, Luzhou, PR China

Chuankang Tang

Department of Gastroenterology, The Affliliated Hospital of Southwest Medical University, Luzhou, PR China

Corresponding Author(s) : Chuankang Tang

twdg46@163.com

Cellular and Molecular Biology, Vol. 66 No. 1: Issue 1
Article Published : April 20, 2020

Abstract

Gastric cancer (GC) is one of the most common fatal cancers among gastrointestinal malignancies. At present, the treatment of gastric cancer involves a combination of surgery and chemotherapy. Isofebrifugine (IFE) is an alkaloid with many biological properties. In this study, results from MTT, scratch and invasion assays showed that IFE significantly inhibited the proliferation, migration and invasion of SGC7901 gastric cancer cells. Through RT-PCR and Western blot experiments, it was revealed that IFE significantly inhibited the mRNA and protein expressions of MMP-2, MMP-9 and SDF-1 which are closely related to cancer invasion and metastasis. Thus, IFE possesses anti-gastric cancer properties.

Keywords

Isofebrifugine Proliferation Invasion Gastric cancer MMP.

Xu, J., Wu, J., & Tang, C. (2020). Effect of isofebrifugine on the proliferation and invasion of human gastric cancer cells via MMP. Cellular and Molecular Biology, 66(1), 27–31. https://doi.org/10.14715/cmb/2019.66.1.4

Download Citation

References

Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67: 7-30.
Sano T, Coit DG, Kim H, Roviello F, Kassab P, Wittekind C, et al. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer 2017; 20: 217-225.
Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: Epidemiology, prevention, classification, and treatment. Cancer Manag Res 2018; 10: 239-248.
Necula L, Matei L, Dragu D, Neagu AI, Mambet C, Nedeianu S, et al. Recent advances in gastric cancer early diagnosis. World J Gastroenterol 2019; 5: 2029-2044.
Digklia A, Wagner AD. Advanced gastric cancer: Current treatment landscape and future perspectives. World J Gastroenterol 2016; 22: 2403-2414.
Dias DA, Urban S, Roessner U. A historical overview of natural products in drug discovery. Metabolites 2012; 2: 303-336.
Guerra AR, Duarte MF, Duarte IF. Targeting Tumor Metabolism with Plant-Derived Natural Products: Emerging Trends in Cancer Therapy. J Agric Food Chem 2018; 66: 10663-10685.
Hirai S, Kikuchi H, Kim H, Begum K, Wataya Y, Tasaka H, et al. Metabolites of febrifugine and its synthetic analogue by mouse liver S9 and their antimalarial activity against Plasmodium malaria parasite. J Med Chem 2003; 46: 4351-4359.
Takeuchi Y, Koike M, Azuma K, Nishioka H, Abe H, Kim H, et al. Synthesis and antimalarial activity of febrifugine derivatives. Chem Pharm Bull (Tokyo) 2001; 49: 721-725.
Ningthoujam SS, Talukdar AD, Nath D, Basar N, Potsangbam KS, Choudhury M. Febrifugine and its analogs: Studies for their antimalarial and other therapeutic properties. Stud Nat Prod Chem 2015; 44: 93-112.
Mclaughlin NP, Evans P, Pines M. The chemistry and biology of febrifugine and halofuginone. Bioorg Med Chem 2014; 22: 1993-2004.
Leiba M, Cahalon L, Shimoni A, Lider O, Zaninzhorov A, Hecht I, et al. Halofuginone inhibits NF-ÎºB and p38 MAPK in activated T cells. J Leukoc Biol 2006; 80: 399-406.
Pines M. Halofuginone for fibrosis, regeneration and cancer in the gastrointestinal tract. World J Gastroenterol 2014; 20:14778-14786.
Jin ML, Park SY, Kim YH, Park G, Lee SJ. Halofuginone induces the apoptosis of breast cancer cells and inhibits migration via downregulation of matrix metalloproteinase-9. Int J Oncol 2014; 44: 309-318.
Taylorharding B, Orsulic S, Karlan BY, Li AJ. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells. Gynecol Oncol 2010; 119: 549-556.
Zhao C, Tao T, Yang L, Qin Q, Wang Y, Liu H, et al. Loss of PDZK1 expression activates PI3K/AKT signaling via PTEN phosphorylation in gastric cancer. Cancer Lett 2019; 453: 107-121.
Warschkow R, Baechtold M, Leung K, Schmied BM, Nussbaum DP, Gloor B, et al. Selective survival advantage associated with primary tumor resection for metastatic gastric cancer in a Western population. Gastric Cancer 2018; 21: 324-337.
Wang X, Xu L, Lao Y, Zhang H, Xu H. Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs. Curr Protein Pept Sci 2018; 19: 380-388.
Demain AL, Vaishnav P. Natural products for cancer chemotherapy. Microb Biotechnol 2011; 4: 687-699.
Klupp F, Neumann L, Kahlert C, Diers J, Halama N, Franz C, et al. Serum MMP7, MMP10 and MMP12 level as negative prognostic markers in colon cancer patients. BMC Cancer 2016; 16: 494.
Xu J, Changyong E, Yao Y, Ren S, Wang G, Jin H. Matrix metalloproteinase expression and molecular interaction network analysis in gastric cancer. Oncol Lett 2016; 12: 2403-2408.
Merchant N, Nagaraju GP, Rajitha B, Lammata S, Jella KK, Buchwald ZS, et al. Matrix metalloproteinases: Their functional role in lung cancer. Carcinogenesis 2017; 38: 766-780.
Knapinska AM, Estrada C, Fields GB. The Roles of Matrix Metalloproteinases in Pancreatic Cancer. Prog Mol Biol Transl Sci 2017; 148: 339-354.
Oconnor T, Borsig L, Heikenwalder M. CCL2-CCR2 signaling in disease pathogenesis. Endocr Metab Immune Disord Drug Targets 2015; 15: 105-118.
Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 Pathway in Cancer. Clin Cancer Res 2010; 16: 2927-2931.
Zhao B, Han JG, Ma H, Wang ZJ. Adipose-derived stem cells promote gastric cancer cell growth, migration and invasion through SDF-1/CXCR4 axis. Hepatogastroenterology 2010; 57: 1382-1389.
Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, et al. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 2010; 29: 709-722.
Wald O, Shapira OM, Izhar U. CXCR4/CXCL12 Axis in Non Small Cell Lung Cancer (NSCLC) Pathologic Roles and Therapeutic Potential. Theranostics 2013; 3: 26-33.

References

Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67: 7-30.

Sano T, Coit DG, Kim H, Roviello F, Kassab P, Wittekind C, et al. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer 2017; 20: 217-225.

Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: Epidemiology, prevention, classification, and treatment. Cancer Manag Res 2018; 10: 239-248.

Necula L, Matei L, Dragu D, Neagu AI, Mambet C, Nedeianu S, et al. Recent advances in gastric cancer early diagnosis. World J Gastroenterol 2019; 5: 2029-2044.

Digklia A, Wagner AD. Advanced gastric cancer: Current treatment landscape and future perspectives. World J Gastroenterol 2016; 22: 2403-2414.

Dias DA, Urban S, Roessner U. A historical overview of natural products in drug discovery. Metabolites 2012; 2: 303-336.

Guerra AR, Duarte MF, Duarte IF. Targeting Tumor Metabolism with Plant-Derived Natural Products: Emerging Trends in Cancer Therapy. J Agric Food Chem 2018; 66: 10663-10685.

Hirai S, Kikuchi H, Kim H, Begum K, Wataya Y, Tasaka H, et al. Metabolites of febrifugine and its synthetic analogue by mouse liver S9 and their antimalarial activity against Plasmodium malaria parasite. J Med Chem 2003; 46: 4351-4359.

Takeuchi Y, Koike M, Azuma K, Nishioka H, Abe H, Kim H, et al. Synthesis and antimalarial activity of febrifugine derivatives. Chem Pharm Bull (Tokyo) 2001; 49: 721-725.

Ningthoujam SS, Talukdar AD, Nath D, Basar N, Potsangbam KS, Choudhury M. Febrifugine and its analogs: Studies for their antimalarial and other therapeutic properties. Stud Nat Prod Chem 2015; 44: 93-112.

Mclaughlin NP, Evans P, Pines M. The chemistry and biology of febrifugine and halofuginone. Bioorg Med Chem 2014; 22: 1993-2004.

Leiba M, Cahalon L, Shimoni A, Lider O, Zaninzhorov A, Hecht I, et al. Halofuginone inhibits NF-ÎºB and p38 MAPK in activated T cells. J Leukoc Biol 2006; 80: 399-406.

Pines M. Halofuginone for fibrosis, regeneration and cancer in the gastrointestinal tract. World J Gastroenterol 2014; 20:14778-14786.

Jin ML, Park SY, Kim YH, Park G, Lee SJ. Halofuginone induces the apoptosis of breast cancer cells and inhibits migration via downregulation of matrix metalloproteinase-9. Int J Oncol 2014; 44: 309-318.

Taylorharding B, Orsulic S, Karlan BY, Li AJ. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells. Gynecol Oncol 2010; 119: 549-556.

Zhao C, Tao T, Yang L, Qin Q, Wang Y, Liu H, et al. Loss of PDZK1 expression activates PI3K/AKT signaling via PTEN phosphorylation in gastric cancer. Cancer Lett 2019; 453: 107-121.

Warschkow R, Baechtold M, Leung K, Schmied BM, Nussbaum DP, Gloor B, et al. Selective survival advantage associated with primary tumor resection for metastatic gastric cancer in a Western population. Gastric Cancer 2018; 21: 324-337.

Wang X, Xu L, Lao Y, Zhang H, Xu H. Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs. Curr Protein Pept Sci 2018; 19: 380-388.

Demain AL, Vaishnav P. Natural products for cancer chemotherapy. Microb Biotechnol 2011; 4: 687-699.

Klupp F, Neumann L, Kahlert C, Diers J, Halama N, Franz C, et al. Serum MMP7, MMP10 and MMP12 level as negative prognostic markers in colon cancer patients. BMC Cancer 2016; 16: 494.

Xu J, Changyong E, Yao Y, Ren S, Wang G, Jin H. Matrix metalloproteinase expression and molecular interaction network analysis in gastric cancer. Oncol Lett 2016; 12: 2403-2408.

Merchant N, Nagaraju GP, Rajitha B, Lammata S, Jella KK, Buchwald ZS, et al. Matrix metalloproteinases: Their functional role in lung cancer. Carcinogenesis 2017; 38: 766-780.

Knapinska AM, Estrada C, Fields GB. The Roles of Matrix Metalloproteinases in Pancreatic Cancer. Prog Mol Biol Transl Sci 2017; 148: 339-354.

Oconnor T, Borsig L, Heikenwalder M. CCL2-CCR2 signaling in disease pathogenesis. Endocr Metab Immune Disord Drug Targets 2015; 15: 105-118.

Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 Pathway in Cancer. Clin Cancer Res 2010; 16: 2927-2931.

Zhao B, Han JG, Ma H, Wang ZJ. Adipose-derived stem cells promote gastric cancer cell growth, migration and invasion through SDF-1/CXCR4 axis. Hepatogastroenterology 2010; 57: 1382-1389.

Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, et al. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 2010; 29: 709-722.

Wald O, Shapira OM, Izhar U. CXCR4/CXCL12 Axis in Non Small Cell Lung Cancer (NSCLC) Pathologic Roles and Therapeutic Potential. Theranostics 2013; 3: 26-33.

Author biographies is not available.